Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia

Clinica Chimica Acta

Volumn 322, Issue 1-2, 2002, Pages 77-84

  Grady Smith, W ^a,b   Wang, Jiang ^a   Dang, An Q ^a   Reeves, Charles ^a   Bibbs, David ^a   Faas, Fred H ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Gemfibrozil; Hypertriglyceridemia; Lipoproteins

Indexed keywords

CHOLESTEROL ESTER; COPPER; GEMFIBROZIL; LIPID; LIPOPROTEIN; MONOUNSATURATED FATTY ACID; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FATTY ACID BLOOD LEVEL; GAS LIQUID CHROMATOGRAPHY; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; OXIDATION; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; FATTY ACIDS, UNSATURATED; GEMFIBROZIL; HUMANS; HYPERTRIGLYCERIDEMIA; LIPIDS; LIPOPROTEINS; OXIDATION-REDUCTION; TIME FACTORS;

EID: 0036298479     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(02)00129-8     Document Type: Article

References (39)

1. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenecity
2. Oxidative modification of LDL and atherogenesis. The 1995 Lewis A. Conner Memorial Lecture
3. Feasibility of using an oleate-rich diet to reduce the susceptibility of low-density lipoprotein to oxidative modification in humans
4. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies
5. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies
6. How different constituents of human plasma and low-density lipoprotein determine plasma oxidizability by copper
7. Oxidation of low-density lipoproteins: Effect of antioxidant content, fatty acid composition and intrinsic phospholipase activity on susceptibility to metal ion-induced oxidation
8. Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: Studies in vitamin E deficient subjects
9. Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation
10. Low-density lipoprotein rich in oleic acid is protected against oxidative modification: Implications for dietary prevention of atherosclerosis
11. How different constituents of low-density lipoprotein determine its oxidizability by copper: A correlational approach
12. Safety considerations of polyunsaturated fatty acids
13. Antioxidant protection of LDL by physiological concentrations of 17-beta estradiol. Requirement for estradiol modification
14. Calcium-channel blockers inhibit low-density lipoprotein oxidation by oxygen radicals
15. Effects of in vitro addition of captopril on copper-induced low-density lipoprotein oxidation
16. Troglitazone increases the resistance of low-density lipoprotein to oxidation in healthy volunteers
17. The effects of gliciazide and other sulfonylureas on low-density lipoprotein oxidation in vitro
18. Decreased susceptibility to copper-induced oxidation of rat lipoproteins after fibrate treatment: Influence of fatty acid composition
19. Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats
20. Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea pigs
21. Helsinki heart study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
22. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidemia
23. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
24. Gemfibrozil in hyperlipidemic patients with peripheral arterial disease: Some undiscovered actions
25. Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia
26. Beneficial effect of gemfibrozil on the chemical composition and oxidative. Susceptibility of low-density lipoprotein: A randomized, double-blind, placebo-controlled study
27. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients
28. Comparison of gemfibrozil vs. simvistatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density-lipoprotein subfraction profile and low-density-lipoprotein oxidizability
29. Lipoprotein composition and oxidative modification during drug therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia
30. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low-density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia
31. Gemfibrozil treatment increases low-density lipoprotein particle size in type 2 diabetes mellitus but does not alter in vitro oxidizability
32. Effect of gemfibrozil on fatty acids in lipid fractions of plasma from patients with hypertriglyceridemia
33. Simple and rapid assessment of lipoprotein susceptibility to oxidation in the macromolecule fraction of plasma
34. Lipoprotein susceptibility to oxidation in the macromolecular fraction of plasma: Relation to plasma lipids and oleate/linoleate ratio in comparison with whole plasma in hypertriglyceridemia
35. Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia - Effects of bezafibrate therapy
36. Methods to determine oxidation of low-density lipoproteins
37. Altered fatty acid composition in the plasma, platelets and aorta of the streptozotocin-induced diabetic rat
38. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia